Brainsway® Announces Positive Final Results of its Deep TMS Multicenter Study in Obsessive Compulsive Disorder (OCD) Patients Brainsway will prepare a submission to the FDA to market the device for OCD Deep TMS treatment led to statistically significant and meaningful improvements in patients suffering from OCD Patients...

New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1 ROCKVILLE, Md., April 18, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced the publication of a new study in an...

ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients LEIDEN, the Netherlands, Oct. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that clinical study PQ-010-002, a proof-of-concept study of nasal potential...

Sucampo Announces Presentation of Results on AMITIZA(R) (lubiprostone) in Opioid-Induced Constipation at Two Upcoming Scientific Conferences BETHESDA, Md., Oct. 11, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced the presentation of three posters evaluating AMITIZA® (lubiprostone) in...